1.02Open1.02Pre Close0 Volume3 Open Interest2.50Strike Price0.00Turnover241.89%IV12.43%PremiumDec 20, 2024Expiry Date0.81Intrinsic Value100Multiplier26DDays to Expiry0.21Extrinsic Value100Contract SizeAmericanOptions Type-0.6104Delta0.3528Gamma1.66Leverage Ratio-0.0079Theta-0.0012Rho-1.01Eff Leverage0.0017Vega
ProKidney Stock Discussion
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting
Positive
FDA confirmation that PROACT 1 Phase 3 study could be sufficient for full regulatory approval
Accelerated approval pathway available with eGFR slope as surrogate endpoint
Strong cash position of $406.8 million, supporting operations into 2027
Reduced R&D expenses by $0.9 million year-over-year
Slight improvement...
SEC· 11 mins ago
ProKidney Announces Strategic Updates to Its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S. Believes Phase 3 Regen-016 (Proact 2) Trial Is Not Required for Initial U.S. Registration
ProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
No comment yet